Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "PAT"

6748 News Found

Akums Drugs gets 20- year patent for
News | November 04, 2025

Akums Drugs gets 20- year patent for "Dual Release Gastro-Resistant Composition"

The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease


Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
News | November 04, 2025

Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr

Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal


Dr Lal Path Labs reports consolidated Q2 FY26 PAT at Rs. 150.6 Cr
News | November 02, 2025

Dr Lal Path Labs reports consolidated Q2 FY26 PAT at Rs. 150.6 Cr

The company has posted net profit of Rs. 283 crore for the 6 months period ended September 30, 2025


Dr Agarwals Health Care posts consolidated Q2 FY26 PAT at Rs. 29.69 Cr
News | November 02, 2025

Dr Agarwals Health Care posts consolidated Q2 FY26 PAT at Rs. 29.69 Cr

Dr Agarwals Health Care has reported total income of Rs. 506.62 crore during the period ended September 30, 2025


Dabur India reports consolidated Q2 FY26 PAT at Rs. 452.55 Cr
News | November 02, 2025

Dabur India reports consolidated Q2 FY26 PAT at Rs. 452.55 Cr

Dabur India has reported total income of Rs. 3,331.45 crore during the period ended September 30, 2025


Dr. Agarwals Eye Hospital posts consolidated Q2 FY26 PAT at Rs. 19.32 Cr
News | November 02, 2025

Dr. Agarwals Eye Hospital posts consolidated Q2 FY26 PAT at Rs. 19.32 Cr

Dr Agarwals Eye Hospital has reported total income of Rs. 118.40 crore during the period ended September 30, 2025


Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr
News | November 02, 2025

Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr

Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025


Tatva Chintan Pharma Chem reports consolidated Q2 FY26 PAT at Rs. 9.91 Cr
News | November 02, 2025

Tatva Chintan Pharma Chem reports consolidated Q2 FY26 PAT at Rs. 9.91 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 124.52 crore during the period ended September 30, 2025